证券代码：300399 证券简称：天利科技 江西天利科技股份有限公司投资者关系活动记录表 | | 的思路推进各项工作，具体措施上，鼓励各业务条线实现自我突破，并通 | | --- | --- | | | 过"赛马"及配套奖惩措施保障总体目标的落地，关于公司发展的详细信 | | | 息请您关注公司定期报告。感谢您的关注。 | | | 5、天利科技，目前公司营收太少，公司是否会进行资产购买，并购 | | | 重组来增加公司实力 | | | 尊敬的投资者，您好！公司目前暂无相关计划，您的意见建议公司已 | | | 收悉，后续公司如有涉及相关事项，将严格按照信息披露要求进行披露。 | | | 感谢您的关注。 | | | 6、公司有没有重组预期 | | | 尊敬的投资者，您好！公司目前暂无重组计划，后续如有涉及将严格 | | | 根据相关规定及时履行信息披露义务。感谢您的关注。 | | 附件清单（如有） 无 | | | 日期 | 2025-05-21 16:59:54 | 编号：2025-002 号 投资者关系活动类 别 □特定对象调研 □ 分析师会议 □ 媒体采访 √ 业绩说明会 □ 新闻发布会 □ 路演活动 □ 现 ...

5月13日，市场监管总局会同中央社会工作部、中央网信办、人力资源社会保障部等五部门联合约谈京东、美团、饿了幺三大外卖平台，要求其"合法规范经 营，公平有序竞争"，以及"切实维护消费者、平台内经营者和外卖骑手的合法权益"。 同日，京东发布了新增外卖业务后的首份业绩报告。作为今年2月刚刚上线、且从3月1日起开始为京东外卖全职骑手缴纳五险一金而备受关注的新增业务， 京东外卖没有被纳入零售或物流业务线，而是被纳入了包括达达、京东产发、京喜、海外业务在内的新业务体系。 根据京东2025年一季度财报数据，其新业务收入达到57.53亿元，同比增加8.83亿元。然而，亏损局面仍然未能扭转，经营利润率反而从-13.8%进一步扩大 至-23.1%，亏损规模较上年同期几乎翻倍。 尽管京东的外卖业务并非独立业务，其与京东生态的深度融合，与京东的电商销售、实时零售（如七鲜超市）以及物流等业务形成的协同发展效应，包括升 级京东的末端配送网络，以及促进用户增长和互动，这些都能够给市场带来极大的想象空间。但也不容忽视这种快速扩张带来的成本增幅。 | | | 截至以下目期止三個月 | | | --- | --- | --- | --- | | ...

点击蓝字，关注我们 主要逻辑： 电商+游戏+数字金融，三大业务板块协同驱动业绩高增；公司早期"以价换量"的货币化措施开始 放量，并在竞争中取得阶段性胜利，利润率得到有效提升；市场或低估其在东南亚的垄断地位。 股价近一年涨幅达140%，截至5月15日收盘，远期市盈率达45x。 鉴于东南亚及巴西的高增长属性， 市场对其未来增速的预期显著高于同在电商领域的eBay、京东和纯数字金融的PayPal、block，亦高于 一直被拿来对标的腾讯。 | | 宮号 | 证券代码 | 让券简称 | 预测PE(NTM) | 销售利润率(N年,增长率) | 营业收入(同比增长率) | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | [交易日期] 最新收祭日 | [报告期] 最新一期(MRQ) | [报告期] 今年一季 | | | | | | | [单位] 倍 | [年数] 3 | [单位] % | | | | | | | | [单位] % | | | | | 1 2 | SE.N SHOP.O | SEA SHOPIFY | 44.7151 100.0758 ...

证券代码：301525 证券简称：儒竞科技 上海儒竞科技股份有限公司 投资者关系活动记录表 编号： 2025-002 投资者关系活动 类别 □特定对象调研 □分析师会议 □媒体采访 ☑业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 （ ） 参与单位名称 参加 2025 年上海辖区上市公司年报集体业绩说明会的投资者 时间 2025 年 5 月 15 日 地点 上证路演中心平台 上市公司接待人 员姓名 董事长、总经理：雷淮刚 先生 独立董事：朱军生 先生 董事会秘书、财务总监：厉昊超 女士 投资者关系活动 主要内容介绍 一、董事会秘书致开场辞 尊敬的各位投资者： 大家好！我是上海儒竞科技股份有限公司财务总监兼董事会秘书厉昊 超。在此，我谨代表公司向参加本次业绩说明会的各位投资者表示热烈的 欢迎和衷心的感谢。同时，感谢上证路演中心为本次公司业绩说明会提供 网络平台支持。 出席本次业绩说明会的嘉宾还有公司董事长、总经理雷淮刚先生、独 立董事朱军生先生。公司召开本次业绩说明会，是为了便于广大投资者更 全面深入地了解公司情况，公司将积极与广大投资者进行交流，就大家所 关心的有关公司经营和发展方面的问题进行探讨， ...

Investment Rating - The report maintains an "Accumulate" rating for the company [4] Core Views - The company's revenue and net profit growth in 2024 are primarily driven by the synergistic development in the television and LED industries, alongside advancements in optical communication and video network sectors [2][9] - The company has successfully expanded its television business, achieving a revenue of 14.996 billion yuan in 2024, a year-on-year increase of 18.43%, with a shipment volume of 12.5 million units, up 14% year-on-year [3] - The report highlights the company's focus on cost control and enhancing product value, contributing to its profitability despite a slight decline in gross and net profit margins [2][9] Financial Summary - For 2024, the company achieved a revenue of 20.326 billion yuan, a year-on-year growth of 18.4%, and a net profit of 1.602 billion yuan, a year-on-year increase of 0.89% [1] - The projected revenues for 2025 to 2027 are 21.465 billion yuan, 24.083 billion yuan, and 27.527 billion yuan, respectively, with corresponding net profits of 1.732 billion yuan, 2.029 billion yuan, and 2.493 billion yuan [1][9] - The company's gross margin for 2024 was 17.17%, a decrease of 1.66 percentage points year-on-year, while the net margin was 8.52%, down 1.09 percentage points year-on-year [2]

Revvity (RVTY) 2025 Conference Summary Company Overview - **Company**: Revvity (RVTY) - **Date**: May 13, 2025 - **Industry**: Life Sciences Tools and Diagnostics Key Points 1. Q1 Performance and Guidance - The first quarter showed solid performance despite a different macro environment than initially assumed for 2025 guidance [4][5] - The diagnostics and software businesses performed exceptionally well, contributing to the overall strength of the portfolio [4][5] - The company maintained full-year guidance despite a weaker macro backdrop due to prudent initial guidance [5] 2. Tariff Impact and Mitigation Strategies - Gross tariff headwinds were estimated at $135 million, with a net impact of approximately $0.12 on EPS after operational mitigation [6][12] - The majority of tariff impacts are expected in the second quarter, with operational mitigation strategies being implemented [6][12] - The company has a dual manufacturing strategy to enhance supply chain resiliency, including a GMP facility in San Diego and another outside the US [10] 3. Academic and Government Market Exposure - Academic and government customers account for 12% of global revenue, with over 5% in the US [21] - There is cautiousness in these segments due to uncertainties around indirect expense reimbursements and NIH funding levels [22][24] 4. Pharma and Biotech Market Trends - The pharma and biotech sectors showed positive growth in Q1, but there is uncertainty due to macroeconomic factors and tariffs [28] - Instrumentation sales are expected to face continued pressure, particularly from mid and large-sized pharma customers [29][30] 5. Geographic Performance - China represents 16% of total revenue, with diagnostics showing high single-digit growth while life sciences experienced a slight decline [34] - The company anticipates continued choppiness in the China life sciences market but modest growth in diagnostics [34][35] 6. Software Business Strength - The software business is highlighted as a major area of strength, with new product launches and a focus on large molecule capabilities [48][49] - The company is expanding into new customer groups and markets, such as material science, which has shown good traction [49] 7. Margin Expectations and Cost Management - The company expects balanced margin expectations for the year, with temporary belt-tightening measures in place to mitigate tariff impacts [50][51] - There are no plans for additional structural cost reductions, but ongoing monitoring will occur [51] 8. Capital Allocation and M&A Strategy - Revvity has adopted a balanced approach to capital deployment, including share buybacks and selective M&A opportunities [55][56] - The company is cautious about M&A in the current market, noting that private companies are not in a rush to sell despite lower valuations [57][59] 9. Underappreciated Aspects of Revvity - The company’s differentiated portfolio and execution capabilities are not fully recognized in the market [61][62] - There is potential for margin expansion that has yet to be demonstrated due to current market pressures [62][63] 10. Future Outlook - The company remains optimistic about its long-term growth potential, particularly in the reagents business and software capabilities [41][48] - Continued execution and clarity in macroeconomic conditions are essential for demonstrating the company's margin expansion opportunities [63] This summary encapsulates the key insights and data points from the Revvity conference, providing a comprehensive overview of the company's current performance, challenges, and strategic outlook.

Terex (TEX) Q1 2025 Earnings Call May 02, 2025 08:00 AM ET Company Participants Derek Everitt - Vice President, Investor RelationsSimon A. Meester - President & CEOJennifer Kong-Picarello - SVP & CFOJerry Revich - Senior Investment Leader & Head of US Machinery, Infrastructure, Sustainable Tech franchiseJamie Cook - Managing Director - Equity ResearchDavid Raso - Senior Managing Director & PartnerTami Zakaria - Executive DirectorAngel Castillo - Executive Director Conference Call Participants Mircea Dobre - ...

JinkoSolar (JKS) Q1 2025 Earnings Call April 29, 2025 08:30 AM ET Company Participants Stella Wang - Investor RelationsGener Miao - Chief Marketing OfficerMengmeng Li - Chief Financial OfficerTyler Bisset - Equity Research AssociateHaiyun Cao - DirectorRajiv Chaudhri - President Conference Call Participants Philip Shen - Managing Director, Senior Research AnalystAlan Lau - Analyst Operator a reminder, today's conference call is being recorded. I would now like to turn the meeting over to your host for today ...